公开(公告)号：US20200016057A1

公开(公告)日：2020-01-16

申请号：US16579122

申请日：2019-09-23

Applicant: Ajinomoto Co., Inc.

Inventor： Yoshinobu TAKINO ,  Sachise KARAKAWA ,  Fumie OKURA ,  Eri IKEGAMI

IPC: A61K8/44 ,  A61K8/49 ,  A61Q19/02

Abstract: Agents which contain at least one D-amino acid selected from the group consisting of D-asparagine, D-valine, D-allo-threonine, D-lysine, D-glutamine, D-histidine, D-leucine, D-phenylalanine, D-serine, D-tryptophan, and D-tyrosine are useful as whitening agents and are effective in preventing and inhibiting melanin pigmentation such as pigmented spot, freckles, and somberness.

公开(公告)号：US20250027949A1

公开(公告)日：2025-01-23

申请号：US18906699

申请日：2024-10-04

Applicant: AJINOMOTO CO., INC.

Inventor： Koichi AZUMA ,  Kenta MUROTANI ,  Tetsuro SASADA ,  Tomoyuki TAGAMI ,  Asami HAGIWARA ,  Akira IMAIZUMI ,  Sachise KARAKAWA ,  Mika KAWASAKI ,  Yohei MIYAGI ,  Tomohiko TAMURA ,  Haruhiro SAITO ,  Yoshiro NAKAHARA ,  Feifei WEI ,  Rika KASAJIMA ,  Huihui XIANG ,  Tatsuma BAN

IPC: G01N33/68

Abstract: An evaluating method includes an evaluating step of evaluating a relative pharmacological action of a combination of an immune checkpoint inhibitor and an anticancer drug as a combination drug compared with a pharmacological action of an immune checkpoint inhibitor alone in a subject to be evaluated, using (i) a concentration value of at least one metabolite among Glu, Arg, Orn, Cit, His, Val, Phe, Tyr, Met, Pro, Asn, Leu, Lys, Thr, Ile, Gln, Ala, Ser, a-ABA, Trp, Gly, AnthA, hKyn, hTrp, Kyn, KynA, NP, QA, and XA in blood of the subject to be evaluated, or (ii) a value of a formula in the absence of use of an anticancer drug as a combination drug and a value of the formula in the presence of the use that are calculated using the concentration value and the formula including an explanatory variable to be substituted with the concentration value and an explanatory variable on the presence or absence of the use.

公开(公告)号：US20240219394A1

公开(公告)日：2024-07-04

申请号：US18432550

申请日：2024-02-05

Applicant: AJINOMOTO CO., INC.

Inventor： Chiori IJICHI ,  Yusuke IHARA ,  Yasuko SOMEKAWA ,  Yayoi KAWATO ,  Sachise KARAKAWA

IPC: G01N33/68 ,  G01N33/74

CPC classification number: G01N33/68 ,  G01N33/74 ,  G01N2333/726 ,  G01N2500/04 ,  G01N2500/10

Abstract: A method for measuring a response of an olfactory receptor to a substance is provided. The test substance and the olfactory receptor are contacted under such a condition that response of adenosine receptor to the test substance is reduced, and response of the olfactory receptor to the test substance is measured.

公开(公告)号：US20240018272A1

公开(公告)日：2024-01-18

申请号：US18460810

申请日：2023-09-05

Applicant: AJINOMOTO CO., INC.

Inventor： Yuichi NAKAHARA ,  Yuta ENDO ,  Ippei INOUE ,  Takahiro OKASORA ,  Junko YAMAZAKI HOSHIDA ,  Sachise KARAKAWA

IPC: C07K17/04 ,  C07K14/435

CPC classification number: C07K17/04 ,  C07K14/435

Abstract: the present invention provides a method for producing a protein having a supramolecular structure in which a bioactive substance is encapsulated, comprising: (I) bringing a subunit of a protein, which forms a supramolecular structure, a bioactive substance, and a solution for forming the protein having the supramolecular structure from the subunit into contact with one another in a flow micro mixer.

公开(公告)号：US20220268790A1

公开(公告)日：2022-08-25

申请号：US17730484

申请日：2022-04-27

Applicant: AJINOMOTO CO., INC.

Inventor： Sachise KARAKAWA ,  Tomoyuki TAGAMI ,  Rumi NISHIMOTO ,  Shinya KIKUCHI ,  Akira IMAIZUMI ,  Koichi AZUMA ,  Tomoaki HOSHINO ,  Takaaki TOKITO ,  Hidenobu ISHII ,  Norikazu MATSUO

IPC: G01N33/94 ,  G01N33/68 ,  G16H10/40 ,  G16H50/30

Abstract: An evaluating method includes an evaluating step of evaluating a pharmacological action of an immune checkpoint inhibitor in a subject to be evaluated, using (i) a concentration value of at least one metabolite among Glu, Arg, Orn, Cit, His, Val, Phe, Tyr, Met, Pro, Asn, Leu, Lys, Thr, Ile, Gln, Ala, Ser, a-ABA, Trp, Gly, AnthA, hAnthA, hIAA, hKyn, hTrp, IAA, ILA, Kyn, KynA, NFKyn, NP, PA, QA, Serot, and XA in blood of the subject to be evaluated, or (ii) a value of a formula calculated using the concentration value and the formula including an explanatory variable to be substituted with the concentration value.